
First patient dosed in trial of Geographic Atrophy treatment
The first patient has been dosed in a first-in-human clinical trial of a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). CTx001, developed by biotechnology company Complement Therapeutics, is being evaluated in the Phase I/II Opti-GAIN study evaluating its safety, tolerability and preliminary efficacy. … Read More






